Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH
Video Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH -Copyright ©2022 by PanNash™ Initiative - All rights reserved.
So the diabetologists are recognizing that they have to do more to combat NASH (non-alcoholic steatohepatitis). Slowly but surely they realize their patients with type 2 diabetes have fatty liver and we know that 2 out of 3 patients with type 2 diabetes have a fatty liver. From our studies in the past 15 years, perhaps as many as 40% have NASH. Some large studies have shown if you’re screening a patient with diabetes with a fatty liver, about 15% – 18% have fibrosis stage 2 or greater. This is a big problem which has been recognized, but the number of initiatives to educate diabetologists in the United States and across the world have increased so I’m sure they will turn this around very fast.
- Prof. Kenneth Cusi
- September 13, 2019
- More Comorbidities, Diagnosis
Would you like to read more?
Prof. Kenneth Cusi
Nordic NASH Symposium
PanNASH speaker; Dr. Stephen Harrison takes part in the Nordic NASH symposium which aims to discuss management and diagnosis strategies…
The role of circadian clocks in the pathogenesis of NAFLD
The circadian clock controls rhythms responsible for regulating bodily functions, e.g., appropriate eating times. When this clock becomes disrupted due…
Hepatocellular carcinoma surveillance in NAFLD patients
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver…
MAFLD and inflammatory bowel disease: a prospective cohort study
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
B cells aggravate NASH: an innate and adaptive signalling
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B…
NAFLD: from drivers to targets
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the…
NASH: an Overview Through 200 Years of Clinical Research
Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH)…
Immune cell-mediated features of NASH
In this review, T. Huby and E. L. Gautier (Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France) discuss “current concepts…
Steatohepatitis: hypothesis for a pathomechanism
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases…
Fatty liver through the ages: Nonalcoholic steatohepatitis
In this article, Z. M. Younossi et al. (Inova Health System, Falls Church, VA, USA) aimed to review the current…
Parsing the role of PPARs in macrophage processes
In this review, D. Toobian et al. (University of California San Diego, CA, USA) underline emerging evidence of the potential…
Video SERIES
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
